Journal article
A randomised, double blind comparison of tecarfarin, a novel vitamin K antagonist, with warfarin
Abstract
Tecarfarin is a novel vitamin K antagonist that is metabolised by carboxyl estererase, thereby eliminating the variability associated with cytochrome-mediated metabolism. EmbraceAC was designed to compare the quality of anticoagulation with tecarfarin and warfarin as determined by time in therapeutic range (TTR). In this phase 2/3 randomised and blinded trial, 607 patients with indications for chronic anticoagulation were assigned to warfarin …
Authors
Whitlock RP; Fordyce CB; Midei MG; Ellis D; Garcia D; Weitz JI; Canafax DM; Albrecht D; Milner PG
Journal
Thrombosis and Haemostasis, Vol. 116, No. 02, pp. 241–250
Publisher
Thieme
Publication Date
2 2016
DOI
10.1160/th15-11-0910
ISSN
0340-6245